These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 7909535

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacists' reactions to the Wisconsin Medicaid drug-use review program.
    Brown CM, Lipowski EE.
    Am J Hosp Pharm; 1993 Sep; 50(9):1898-902. PubMed ID: 7907839
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM, Gerrity MS, Anderson T.
    Eff Clin Pract; 2001 Sep; 4(6):263-70. PubMed ID: 11769299
    [Abstract] [Full Text] [Related]

  • 6. Analysis of anti-epileptic drugs in fee-for-service Wisconsin Medicaid.
    Mergener MA, Carr RM.
    WMJ; 2006 Sep; 105(6):36-9. PubMed ID: 17042418
    [Abstract] [Full Text] [Related]

  • 7. Drug education. Moving ahead the fourth year.
    Seibert DJ.
    Pa Med; 1997 Jan; 100(1):22-4, 26. PubMed ID: 9014488
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs.
    Jacoby A, Smith M, Eccles M.
    Br J Gen Pract; 2003 Feb; 53(487):120-5. PubMed ID: 12817357
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Marked increase in proton pump inhibitors use in Australia.
    Hollingworth S, Duncan EL, Martin JH.
    Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1019-24. PubMed ID: 20623646
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cutting costs by targeting prescribing practices.
    Edouard L, Rawson NS.
    CMAJ; 1994 Jul 01; 151(1):14-5. PubMed ID: 8004553
    [No Abstract] [Full Text] [Related]

  • 15. Determining physicians' knowledge and attitudes when prescribing drugs to treat gastrointestinal disorders.
    Soons KR, Lynch T, Seagrave M, Rolley L.
    Clin Perform Qual Health Care; 1997 Jul 01; 5(2):94-8. PubMed ID: 10167220
    [Abstract] [Full Text] [Related]

  • 16. Impact of a drug utilization review program on high-risk use of prescription controlled substances.
    Daubresse M, Gleason PP, Peng Y, Shah ND, Ritter ST, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2014 Apr 01; 23(4):419-27. PubMed ID: 23881609
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP, Njikam A, Scouflaire SM.
    Sante; 2001 Apr 01; 11(3):185-93. PubMed ID: 11641083
    [Abstract] [Full Text] [Related]

  • 19. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA, Kuppermann M, Richter JE.
    Am J Gastroenterol; 1997 Dec 01; 92(12):2179-87. PubMed ID: 9399748
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.